Cargando…
Platelet-derived circRNAs signature in patients with gastroenteropancreatic neuroendocrine tumors
BACKGROUND: Neuroendocrine tumors (NETs) early diagnosis is a clinical challenge that require a deep understanding of molecular and genetic features of this heterogeneous group of neoplasms. However, few biomarkers exist to aid diagnosis and to predict prognosis and treatment response. In the oncolo...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428534/ https://www.ncbi.nlm.nih.gov/pubmed/37587471 http://dx.doi.org/10.1186/s12967-023-04417-8 |
_version_ | 1785090493198106624 |
---|---|
author | Campolo, Federica Sesti, Franz Feola, Tiziana Puliani, Giulia Faggiano, Antongiulio Tarsitano, Maria Grazia Tenuta, Marta Hasenmajer, Valeria Ferretti, Elisabetta Verrico, Monica Gianfrilli, Daniele Venneri, Mary Anna Isidori, Andrea M. Giannetta, Elisa |
author_facet | Campolo, Federica Sesti, Franz Feola, Tiziana Puliani, Giulia Faggiano, Antongiulio Tarsitano, Maria Grazia Tenuta, Marta Hasenmajer, Valeria Ferretti, Elisabetta Verrico, Monica Gianfrilli, Daniele Venneri, Mary Anna Isidori, Andrea M. Giannetta, Elisa |
author_sort | Campolo, Federica |
collection | PubMed |
description | BACKGROUND: Neuroendocrine tumors (NETs) early diagnosis is a clinical challenge that require a deep understanding of molecular and genetic features of this heterogeneous group of neoplasms. However, few biomarkers exist to aid diagnosis and to predict prognosis and treatment response. In the oncological field, tumor-educated platelets (TEPs) have been implicated as central players in the systemic and local responses to tumor growth, thereby altering tumor specific RNA profile. Although TEPs have been found to be enriched in RNAs, few studies have investigated the potential of a type of RNA, circular RNAs (circRNA), as platelet-derived biomarkers for cancer. In this proof-of-concept study, we aim to demonstrate whether the circRNAs signature of tumor educated platelets can be used as a liquid biopsy biomarker for the detection of gastroenteropancreatic (GEP)-NETs and the prediction of the early response to treatment. METHODS: We performed a 24-months, prospective proof-of-concept study in men and women with histologically proven well-differentiated G1-G2 GEP-NET, aged 18–80 years, naïve to treatment. We performed a RNAseq analysis of circRNAs obtained from TEPs samples of 10 GEP-NETs patients at baseline and after 3 months from therapy (somatostatin analogs or surgery) and from 5 patients affected by non-malignant endocrinological diseases enrolled as a control group. RESULTS: Statistical analysis based on p < 0.05 resulted in the identification of 252 circRNAs differentially expressed between GEP-NET and controls of which 109 were up-regulated and 143 were down-regulated in NET patients. Further analysis based on an FDR value ≤ 0.05 resulted in the selection of 5 circRNAs all highly significant downregulated. The same analysis on GEP-NETs at baseline and after therapy in 5 patients revealed an average of 4983 remarkably differentially expressed circRNAs between follow-up and baseline samples of which 2648 up-regulated and 2334 down-regulated, respectively. Applying p ≤ 0.05 and FDR ≤ 0.05 filters, only 3/5 comparisons gave statistically significant results. CONCLUSIONS: Our findings identified for the first time a circRNAs signature from TEPs as potential diagnostic and predictive biomarkers for GEP-NETs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04417-8. |
format | Online Article Text |
id | pubmed-10428534 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-104285342023-08-17 Platelet-derived circRNAs signature in patients with gastroenteropancreatic neuroendocrine tumors Campolo, Federica Sesti, Franz Feola, Tiziana Puliani, Giulia Faggiano, Antongiulio Tarsitano, Maria Grazia Tenuta, Marta Hasenmajer, Valeria Ferretti, Elisabetta Verrico, Monica Gianfrilli, Daniele Venneri, Mary Anna Isidori, Andrea M. Giannetta, Elisa J Transl Med Research BACKGROUND: Neuroendocrine tumors (NETs) early diagnosis is a clinical challenge that require a deep understanding of molecular and genetic features of this heterogeneous group of neoplasms. However, few biomarkers exist to aid diagnosis and to predict prognosis and treatment response. In the oncological field, tumor-educated platelets (TEPs) have been implicated as central players in the systemic and local responses to tumor growth, thereby altering tumor specific RNA profile. Although TEPs have been found to be enriched in RNAs, few studies have investigated the potential of a type of RNA, circular RNAs (circRNA), as platelet-derived biomarkers for cancer. In this proof-of-concept study, we aim to demonstrate whether the circRNAs signature of tumor educated platelets can be used as a liquid biopsy biomarker for the detection of gastroenteropancreatic (GEP)-NETs and the prediction of the early response to treatment. METHODS: We performed a 24-months, prospective proof-of-concept study in men and women with histologically proven well-differentiated G1-G2 GEP-NET, aged 18–80 years, naïve to treatment. We performed a RNAseq analysis of circRNAs obtained from TEPs samples of 10 GEP-NETs patients at baseline and after 3 months from therapy (somatostatin analogs or surgery) and from 5 patients affected by non-malignant endocrinological diseases enrolled as a control group. RESULTS: Statistical analysis based on p < 0.05 resulted in the identification of 252 circRNAs differentially expressed between GEP-NET and controls of which 109 were up-regulated and 143 were down-regulated in NET patients. Further analysis based on an FDR value ≤ 0.05 resulted in the selection of 5 circRNAs all highly significant downregulated. The same analysis on GEP-NETs at baseline and after therapy in 5 patients revealed an average of 4983 remarkably differentially expressed circRNAs between follow-up and baseline samples of which 2648 up-regulated and 2334 down-regulated, respectively. Applying p ≤ 0.05 and FDR ≤ 0.05 filters, only 3/5 comparisons gave statistically significant results. CONCLUSIONS: Our findings identified for the first time a circRNAs signature from TEPs as potential diagnostic and predictive biomarkers for GEP-NETs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04417-8. BioMed Central 2023-08-16 /pmc/articles/PMC10428534/ /pubmed/37587471 http://dx.doi.org/10.1186/s12967-023-04417-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Campolo, Federica Sesti, Franz Feola, Tiziana Puliani, Giulia Faggiano, Antongiulio Tarsitano, Maria Grazia Tenuta, Marta Hasenmajer, Valeria Ferretti, Elisabetta Verrico, Monica Gianfrilli, Daniele Venneri, Mary Anna Isidori, Andrea M. Giannetta, Elisa Platelet-derived circRNAs signature in patients with gastroenteropancreatic neuroendocrine tumors |
title | Platelet-derived circRNAs signature in patients with gastroenteropancreatic neuroendocrine tumors |
title_full | Platelet-derived circRNAs signature in patients with gastroenteropancreatic neuroendocrine tumors |
title_fullStr | Platelet-derived circRNAs signature in patients with gastroenteropancreatic neuroendocrine tumors |
title_full_unstemmed | Platelet-derived circRNAs signature in patients with gastroenteropancreatic neuroendocrine tumors |
title_short | Platelet-derived circRNAs signature in patients with gastroenteropancreatic neuroendocrine tumors |
title_sort | platelet-derived circrnas signature in patients with gastroenteropancreatic neuroendocrine tumors |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428534/ https://www.ncbi.nlm.nih.gov/pubmed/37587471 http://dx.doi.org/10.1186/s12967-023-04417-8 |
work_keys_str_mv | AT campolofederica plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors AT sestifranz plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors AT feolatiziana plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors AT pulianigiulia plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors AT faggianoantongiulio plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors AT tarsitanomariagrazia plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors AT tenutamarta plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors AT hasenmajervaleria plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors AT ferrettielisabetta plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors AT verricomonica plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors AT gianfrillidaniele plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors AT vennerimaryanna plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors AT isidoriandream plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors AT giannettaelisa plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors |